SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-246370
Filing Date
2022-09-16
Accepted
2022-09-16 16:09:05
Documents
14
Period of Report
2022-09-16
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d386213d8k.htm   iXBRL 8-K 27485
2 EX-99.1 d386213dex991.htm EX-99.1 13340
6 GRAPHIC g386213dsp004.jpg GRAPHIC 243819
  Complete submission text file 0001193125-22-246370.txt   509800

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikt-20220916.xsd EX-101.SCH 2863
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20220916_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20220916_pre.xml EX-101.PRE 11713
8 EXTRACTED XBRL INSTANCE DOCUMENT d386213d8k_htm.xml XML 3469
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 221248165
SIC: 2836 Biological Products, (No Diagnostic Substances)